Jpn. J. Pharmacol. 83 (2), 113-118 (2000)
Effects of Rolipram, a Selective Inhibitor of Phosphodiesterase 4,
on Hyperlocomotion Induced by Several Abused Drugs in Mice
Tomohisa Mori1, Jun Baba1, Yasuyuki Ichimaru1,*
and Tsutomu Suzuki2
1PharmaceuticalÊResearch Center, Meiji Seika Kaisha, Ltd.,
760 Morooka-cho, Kohoku-ku, Yokohama 222-8567, Japan
2DepartmentÊof Toxicology, School of Pharmacy, Hoshi University,
Shinagawa-ku, Tokyo 142-8501, Japan
*ÊTo whom correspondence should be addressed.
Abstract: The effects of rolipram, a selective inhibitor of phosphodiesteraseÊ4,
on the hyperlocomotion induced by several abused drugs (methamphetamine,
morphine and phencyclidine) and a dopamineÊD1-receptor agonist
(SKF81297; (±)-6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin
hydrobromide) in mice were investigated. Methamphetamine (0.5-2.0Êmg/kg),
morphine (5.0-20Êmg/kg), phencyclidine (1.25-5.0Êmg/kg) and SKF81297 (2.5-10Êmg/kg)
each induced dose-dependent hyperlocomotion. A low dose (1.0Êmg/kg) or moderate
dose (3.2Êmg/kg) of rolipram suppressed methamphetamine (2.0Êmg/kg)- and
morphine (20Êmg/kg)-induced hyperlocomotion, but not phencyclidine (5.0Êmg/kg)-induced
hyperlocomotion. These results suggest that cAMP in the brain is involved
in methamphetamine- and morphine-induced hyperlocomotion, while the underlying
mechanism(s) of phencyclidine-induced hyperlocomotion may be different from
those of methamphetamine- and morphine-induced hyperlocomotion. It is well
known that methamphetamine- and morphine-induced hyperlocomotion are mediated
by the dopaminergic system and that interaction between postsynapticÊD1-
and D2-receptors may play an important role in the expression
of various dopamine-mediated behaviors. In the present study, SKF81297 (10Êmg/kg)-induced
hyperlocomotion was significantly but not completely suppressed by the highest
dose of rolipram (10Êmg/kg). Therefore it is unlikely that postsynaptic
D1-receptor-mediated functions are involved in the suppressive
effects of rolipram on methamphetamine- and morphine-induced hyperlocomotion.
These results suggest that rolipram may inhibit methamphetamine- and morphine-induced
hyperlocomotion via increase cAMP levels at D2-receptors.
Keywords: Rolipram, Methamphetamine, Phencyclidine, Morphine, SKF81297
Copyright© The Japanese Pharmacological Society 2000
[Back to TOC]